Class 58
The Middle East Outlook Pharmaceutical Market to 2014: policy environment, market structure, competition, economic growth-Aarkstore
Egypt, Turkey, Saudi Arabia, Israel, Jordan, UAE, Lebanon and Kuwait are the main countries of the Middle East with a total population of about 213m. Turkey, a key market pharmerging the world, is a staunch supporter of trade liberalization and policies investment. It has an open trading system, particularly with the countries of the EU, with whom he forged an agreement on customs union 1996. Among the Gulf countries, Saudi Arabia is considered the healthcare market more attractive in the Gulf which is mainly due to its population rapidly growing, enormous economic resources.
The Middle East pharmaceutical market is diverse, with a significant presence of major global players alongside domestic pharmaceutical companies such as Ibrahim Bilim and Deva. The market dynamics are also characterized by the presence several major suppliers of branded generics and API (active pharmaceutical ingredients), such as Teva, Hikma, Ibrahim, etc. Although, the Middle East have been a participant for the latest biotech industry, countries like Turkey, Saudi Arabia, UAE and Israel has made progress spectacular in recent years, which was mainly attributable to several government initiatives. In addition, several public-private partnerships have also stimulated the growth of the pharmaceutical sector in the Middle East.
Key findings
• The Middle East market pharmaceuticals was valued at $ 14.8bn in 2008, registering a yoy growth of 12.6% of sales, and should return to a CAGR of 8.1% between 2008 and 2014 to a total value of 23.5bn in 2014. The market antiinfectives should generate more sales of 3.9 billion dollars in 2014 followed by digestive and metabolic disorders to 3.7 billion dollars.
• General anti-infectives, gastrointestinal tract and metabolism and cardiovascular disease remains the popularity therapeutic categories in the Middle East, while recording 2008 sales of 2.6 billion $ 2.3 billion and $ 1.9, respectively.
• The leading brands in the Middle East pharmaceutical market had a predominance of respiratory medications and cardiovascular. However, the top 10 brands is a very small fraction of the market in the Middle East, with other medicines that constitute 94.1% of total market in 2008. GSK asthma drug Seretide COPD and dominated the market with 2008 sales of $ 134 million, a growth of 21% compared to 2007.
The main features of this report
• The macroeconomic environment in the Middle East countries includes a profile of the population, the burden of morbidity and comparison macro (involving economic landscape and health expenditure) for all major markets in the Middle East
• Profiles of the health system through the 8 markets (Egypt, Turkey, Saudi Arabia, Israel, Jordan, UAE, Lebanon and Kuwait) of the Middle East
• Overview of key recent events in the Middle East market pharmaceutical have influenced patterns of treatment and potential sales in all countries of the Middle East
• Forecasts and analysis of leading products on the Middle East market over the period 2008-14 divided on the main points and types of treatment
Use this report to
• Develop an outline for Middle East pharmaceutical market, pricing and regulations and detailed epidemiological information common risk factors / 8 major countries of the Middle East region
• quickly understand how recent events have an impact on the performance of key products, and how their marketers are facing competitive challenges in the Middle East instead of market
• Gain updated competitive intelligence across a broad range of marketed products, pipeline R & D, market share, sales forecasts and landscape competitive for the major players on the market in the Middle East
Discover
• What are the major growth indications in the Middle East pharmaceutical market over the period 2008-14?
• Which companies (multinational and national) will be the main actors in the Middle East market over the period 2008-14?
• What are the products that will be affected by competition from generic the period 2008-14?
• Which products will be future growth drivers for the pharmaceutical market in the Middle East?
What therapeutic categories are expected to provide significant business opportunities in the forecast period 2008-14
Table Contents:
Introduction
Diabetes mellitus is a chronic metabolic disorder that results due to a failure of the body to produce the hormone insulin and / or inability of the body to respond adequately to circulating insulin. Type 1 diabetes, formerly called diabetes mellitus (IDDM), occurs more frequently in children or young adults and is 5-10% of the population of patients diagnosed with diabetes. Type 2 diabetes, formerly called adult onset diabetes or noninsulin-dependent diabetes mellitus (NIDDM), representing 90-95% of diagnosed diabetes worldwide and usually occurs in middle-aged adults. The prevalence of diabetes mellitus in 2008, and in the seven major markets, was 8.5% with Germany having the highest prevalence rate of 11.8%. But the disease has been increasing at epidemic proportions, a fact which has led R & D in this therapeutic area.
The global market for diabetes was worth $ 27.3bn in 2008 and was directed by insulin like who won 45.0% of the market followed by glitazones which captured a share of 22.8%. United States is the largest market worldwide with diabetes sales of $ 12.9b in 2008 and a market share of 47.6%. But the strongest sales growth year on year has been presented by several leading economies emerging such as the UAE at 59.7%.
Scope of this report
• Epidemiological analysis of prevalence therapeutic area and forecasts for the period 2009-14.
• Forecasts and analysis of key products in the diabetes market in the period 2009-14 located in all major categories of treatment.
• Overview of key events in the global diabetes market have influenced patterns of treatment and potential sales.
• Strategic analysis and growth of large pharmaceutical companies based Sales developed in class drugs, currently on the market and R & D portfolio of products.
Main findings report
• biguanides, mainly consisting of metformin, are the basic salary first line of diabetes care. These drugs been used in the treatment of diabetes by more than a decade. Some advantages include efficiency, low cost, wide experience, the absence of the incidence of hypoglycemia and weight neutrality. Metformin has lost patent protection in 2002 and the class is now much genericized and was transfer of market share to other therapies.
• Insulin captured the largest market share (45%) in diabetics and available treatments is likely to dominate the market in the forecast period. However, if insulin analogues are now well established on the market, inhaled insulin is still to make his mark.
• Major R & D has been observed on the market before insulin leading to the development of several new and safer treatments. The comparative performance of these therapies, such as DPP-IV inhibitors and GLP-1 will shape the landscape of the diabetes market by 2014 and in the long term.
Key issues
• Review of FDA guidelines make the difficult regulatory environment
In December 2008, the FDA announced that companies that develop Diabetes drugs are necessary to conduct longer studies and more in order to avoid any "Unacceptable" cardiovascular risk. The Companies are now required to conduct the meta-analysis for the cardiovascular safety in phase II and III trials and to exclude the possibility ardiovascular of increased disease risk by 80% or more.
• inhaled insulin remains a distant reality
Insulin takes the largest share of treatment of diabetes and has been an area of extensive research. While several different purer forms of insulin have emerged during a period of time, nasally administered insulin is still a distant reality. Inhaled insulin may help compliance, which results in higher long-term. Pfizer / Nektar 's Exubera has been launched for the first inhaled insulin, but it was a launch in difficulty and was subsequently discontinued in October 2007. The only inhaled insulin that is still under development is Technosphere, developed by MannKind / Afresa. This insulin uses a technology that facilitates the absorption of proteins and peptides by the pulmonary route.
Use this report to:
• Which companies were the main actors in the field of diabetes therapy in 2008?
• How have recent launches major key players in the market place?
• Which companies are becoming major players in the diabetes market in the period 2009-14?
• What products will be affected by generic competitors over the period 2009-14?
"Table of Contents
The Middle East Pharmaceutical Market Outlook to 2014
Executive Summary 12
The macroeconomic environment in the Middle East 12
Systems Health in the Middle East 13
Analysis of the pharmaceutical market in the Middle East 14
Market's competitive landscape of the Middle East Pharmaceutical 15
Scope and Methodology 18
Scope 18
Methodology 18
Chapter 1 The macroeconomic environment in the Middle East 20
Summary 20
Introduction 21
Population Profile 22
Burden of disease 24
Comparison of macroeconomic Middle East 30
economic landscape of the main the Middle East 32
Egypt 32
Turkey 33
Saudi Arabia 34
Israel 35
Jordan 36
UAE 36
Lebanon 38
Kuwait 38
Healthcare spent 39
Chapter 2 The health systems in the Middle East 42
Summary 42
Introduction 43
Profiles health systems in countries of the Middle East 43
Egypt 43
The health system 43
IPR 44
Pricing and reimbursement 45
Main events of the last 46
Turkey 47
The health system 47
IPR 49
Pricing and Reimbursement 50
Key Recent Events 52
Saudi Arabia 53
The health system 53
IPR 54
Pricing and reimbursement 55
Major lately 57
Israel 58
The health system 58
Property Rights IP 58
Pricing and reimbursement 59
Main events of the last 61
Jordan 62
The health system 62
rights IP 63
Pricing and reimbursement 63
Main events of the last 64
UAE 65
The health system 65
IPR 66
Pricing and reimbursement 67
Main events of the last 68
Lebanon 68
The system of health 68
IPR 69
Pricing and Reimbursement 70
Main events of the past 71
Kuwait 71
The health system 71
Intellectual property rights 72
Pricing and reimbursement 72
Main Events Past 73
Chapter 3 analyzes the pharmaceutical market in the Middle East 76
Summary 76
Introduction 77
Pharmaceutical Market Overview 77
analysis of the therapeutic range 80
sales forecast therapy area 81
Therapy area analysis by country 82
Egypt 82
Turkey 85
Saudi Arabia 88
Israel 90
Jordan 93
UAE 94
Lebanon 97
Kuwait 100
Major brands analysis 103
Seretide (GSK) 104
Lipitor (Pfizer) 104
Augmentin (GSK / MUP) 104
Gleevec (Novartis) 105
Co-Diovan (Novartis) 105
Spiriva (Boehringer Ingelheim) 106
Plavix (Sanofi-Aventis) 106
Cipralex (Lundbeck) 107
Lansor (Sanovel) 107
Symbicort (AstraZeneca) 108
Sales were marks Forecasts 108
Key brand analysis by country 110
Egypt 110
Flumox and Cefotax (Eipico) 110
Amaryl (Sanofi-Aventis) 111
Cataflam (Novartis) 111
Augmentin (MUP) 111
Turkey 112
Foradil Combi (Novartis) 113
Taxotere (Sanofi-Aventis) 113
Herceptin (Roche) 114
Saudi Arabia 114
Augmentin (GSK) 115
SNAF (Spimaco) 116
(Pfizer) 116
Nexium (AstraZeneca) 116
Israel 116
Norditropin (Novo Nordisk) 117
Seretide (GSK) 118
Tritace (Sanofi-Aventis) 118
Jordan 118
Amoclan (Hikma) 119
Similac Gain Advance and Similac (Abbott Nutrition) 119
Cerelac (Nestle) 120
Arab Emirates United Kingdom 121
(Eli Lilly) 121
Plavix (Sanofi-Aventis) 122
Zinnat (GSK) 122
Lebanon 122
Pariet (J & J) 123
Concor (Merck KGaA) 123
Crestor (AstraZeneca) 124
Kuwait 124
Rocephin (Roche) 125
Xenical (Roche) 125
Yasmin (Bayer) 126
Chapter 4 Competitive Landscape of the East East pharmaceutical market 128
Summary 128
Introduction 129
Key Players 129
Analysis of key players in the Middle East 133
Novartis 133
Overview 133
Sales development in the classroom Drug foreground 133
Marketed product portfolio 135
emphasis Novartis pipeline 138
Analysis of Strategic Growth 139
GSK 142
Overview 142
Sales point class of drugs leading 142
Marketed product portfolio 144
GSK to focus Pipeline 146
analysis of the strategic growth of 147
Sanofi-Aventis 150
Overview 150
Sales focus driving Class 150 drugs
Marketed product portfolio 152
emphasis pipeline Sanofi-Aventis 154
Strategic growth analysis 155
Pfizer 157
Overview 157
Sales focus by drug class leading 157
Marketed product portfolio 159
emphasis Pfizer's pipeline, 161
Strategic growth analysis 162
165 Ibrahim
Overview 165
Sales focus by drug class leading 166
Marketed product portfolio 167
Ibrahim emphasis Pipeline 169
analysis of the strategic growth of 169
Key players analysis Country 171
Egypt 171
Turkey 172
Saudi Arabia 174
Israel 176
Jordan 178
WATER 180
Lebanon 182
Kuwait 183
Chapter 5 Appendix 186
Anatomical Therapeutic Classification (ATC) 186
A: Food tract and metabolism 186
B: blood and blood forming organs 186
C: cardiovascular system 186
D: 187 dermatological
G: Genito-urinary and sex hormones 187
H: Preparations Systemic hormone 187
J: Systemic antiinfectives 187
K: Hospital 187 solutions
L: Antineoplastics and Immunomodulating 187
M: Musculoskeletal System 188
N: Nervous System 188
P: 188 Parasitology
R: respiratory system 188
S: Sensory organs 188
T: 188 diagnostic agents
V: 189 Miscellaneous
Forecast factors 189
Glossary 190
Index 191
LOF
Figure 1.1: Distribution of GDP in major countries of the Middle East, 2008 32
Figure 1.2: Comparison of health spending in major countries of the Middle East 39
Figure 3.3: Middle East pharmaceutical market share by country, 2008 79
Figure 3.4: Top 10 classes of drugs in the Egyptian pharmaceutical market, 2008 ($ m) 85
Figure 3.5: Top 10 classes of drugs on the Turkish market pharmaceuticals, 2008 ($ m) 87
Figure 3.6: Top 10 classes of drugs in Saudi Arabian pharmaceutical market, 2008 ($ m) 90
Figure 3.7: Top 10 classes of drugs in the pharmaceutical market in Israel, 2008 ($ M) 92
Figure 3.8: Top 10 classes of drugs in the Jordanian pharmaceutical market, 2008 ($ m) 94
Figure 3.9: Top 10 classes of drugs in the pharmaceutical market in the UAE, 2008 ($ m) 97
Figure 3.10: Top 10 classes of drugs in the Lebanese pharmaceutical market, 2008 ($ m) 100
Figure 3.11: Top 10 classes of drugs in the pharmaceutical market of Kuwait, 2008 ($ M) 102
Figure 4.12: Market share of top 10 and other actors in the Middle East pharmaceutical market, 2008 132
Figure 4.13: Novartis Middle East sales of the pharmaceutical market by therapy area, 2008 134
Figure 4.14: GSK Middle East pharmaceutical market sales by therapy area, 2008 143
Figure 4.15: Sanofi-Aventis in Middle East sales pharmaceutical market therapy area, 2008 151
Figure 4.16: Pfizer Middle East pharmaceutical market sales by therapy area, 2008 158
Figure 4.17: Ibrahim Middle East, sales of the pharmaceutical market by therapy area, 2008 166
List of Tables
Table 1.1: Demographic Profile major countries Middle East 23
Table 1.2: Forecast epidemiology of risk factors common in Egypt, 2008-14 25
Table 1.3: Forecast Epidemiology of risk factors common in Turkey, 2008-14 25
Table 1.4: Forecast epidemiology of common risk factors, Saudi Arabia, 2008-14 26
Table 1.5: Forecast epidemiology of common risk factors in Israel, 2008-14 27
Table 1.6: Forecast Epidemiology of risk factors common in Jordan, 2008-14 27
Table 1.7: Forecast epidemiology of common risk factors UAE, 2008-14 28
Table 1.8: Forecast epidemiology of common risk factors in Lebanon, 2008-14 29
Table 1.9: Forecast epidemiology risk factors common in Kuwait, 2008-14 30
Table 1.10: Leading economic indicators of countries in the Middle East, 2008 31
Table 3.11: Sales of products pharmaceuticals in major countries of the Middle East, 2008 78
Table 3.12: Middle East, pharmaceutical sales by therapy area, 2008 81
Table 3.13: Middle East sales of the pharmaceutical market provided by the ATC code, 2008-14 82
Table 3.14: Egyptian pharmaceutical market by therapy area sales, 2008 83
Table 3.15: pharmaceutical market in Turkey by therapy area sales, 2008 86
Table 3.16: Saudi pharmaceutical market Arabia breakdown by therapy area sales, 2008 89
Table 3.17: pharmaceutical market of Israel by therapy area sales, 2008 91
Table 3.18: Distribution of the Jordanian pharmaceutical market by therapy area sales, 2008 93
Table 3.19: pharmaceutical market Sales by the United Arab Emirates therapy area, 2008 96
Table 3.20: pharmaceutical market of Lebanon by therapy area sales, 2008 98
Table 3.21: pharmaceutical market by sales of Kuwait therapy area, 2008 101
Table 3.22: leading brands in the Middle East market Pharmaceuticals, 2008 103
Table 3.23: Sales forecasts leading brand, 2008-14 109
Table 3.24: Leading brands in the Egyptian market pharmaceutical 2008 110
Table 3.25: Leading brands in the Turkish market pharmaceuticals, 2008 112
Table 3.26: Leading brands in the Saudi pharmaceutical market, 2008 115
Table 3.27: Leading brands the Israeli pharmaceutical market, 2008 117
Table 3.28: Major brands within the Jordanian market pharmaceuticals 2008 119
Table 3.29: Leading brands in the UAE pharmaceutical market, 2008 121
Table 3.30: Leading brands in the Lebanese pharmaceutical market 2008 123
Table 3.31: Leading brands in the pharmaceutical market of Kuwait, 2008 125
Table 4.32: Companies market leading Middle East Pharmaceutical 2008 130
Table 4.33: Novartis brands on the market in the Middle East, 2008 136
Table 4.34: GSK's brands on the market in the Middle East, 2008 145
Table 4.35: Sanofi-Aventis leading brands on the market in the Middle East, 2008 152
Table 4.36: Pfizer brands in the market in the Middle East, 2008 159
Table 4.37: Ibrahim brands on the market in the Middle East, 2008 168
Table 4.38: Major companies in the Egyptian pharmaceutical market, 2008 171
Table 4.39: Major companies in the Turkish pharmaceutical market, 2008 173
Table 4.40: leading companies in the Saudi market pharmaceuticals 2008 175
Table 4.41: the leading companies in the Israeli pharmaceutical market, 2008 177
Table 4.42: Leading companies in the Jordanian market pharmaceuticals 2008 179
Table 4.43: Major companies in the pharmaceutical market in the UAE, 2008 181
Table 4.44: Major companies in the pharmaceutical industry Lebanese market, 2008 182
Table 4.45: Major Kuwaiti companies in the pharmaceutical market, 2008 184
For more information please contact:
href = "http://www.aarkstore.com/reports/The-Middle-Eastern-Pharmaceutical-Market-Outlook-To-2014-Policy-environment-market-structure-competitive-landscape-growth-opportunities-32327.html "Http://www.aarkstore.com/reports/The-Middle-Eastern-Pharmaceutical-Market-Outlook-To-2014-Policy-environment-market-structure-competitive-landscape-growth-opportunities-32327.html>
About the Author
Minal H
SEO
vinod.minal@gmail.com
http://www.aarkstore.com
Class 58 on Ballast Train
|
|
Hornby 00 class 58 (R332) £22.00 |
|
|
2009 58 Mercedes-Benz Clc Class 200 CDI SPORT 3DR 2.2 £11,990.00 |
|
|
2008 58 MERCEDES-BENZ B CLASS £9,991.00 |
|
|
HORNBY CLASS 58 BATTERY BOX NEW FOR SPARES L5632 £2.99 |
|
|
Hornby Class 58 Diesel “Railfreight” FREE UK POSTAGE £15.00 |
|
|
HORNBY EWS CLASS 58 TRAIN £20.00 |
|
|
Diesel Railway Photograph Class 31 No 5511 at INVERNESS 05-08-58 £0.99 |
|
|
WIDE BRIM BLACK STETSON COWBOY HAT 58cms medium 7 1/8″ fast post 1st class £6.95 |
|
|
RB high class sunglasses aviator lens 58mm BNWT £59.99 |
|
|
Locomotives Illustrated 58 LMS Class ’3P’ 2-6-2 Tanks £4.00 |
|
|
58 MERCEDES-BENZ A CLASS 1.5 A150 CLASSIC SE 5 DOOR £5,795.00 |
|
|
Class 58 Upright Motor To Fit Hornby [New] £4.75 |
|
|
Hornby Class 58 Motorised Chassis. £22.00 |
|
|
1998 Mercedes Benz C-Class 58-page Sales Brochure – C230 C280 £11.99 |
|
|
LADIES RED WATERPROOF TRAPPER HAT 58CM one size fits all,fast post 1st class £4.95 |
|
|
2008 58 MERCEDES-BENZ CLC CLASS £10,950.00 |
|
|
2008 58 MERCEDES-BENZ B CLASS £8,949.00 |
|
|
QUALITY BLACK FELT BOWLER HAT,red satin lining, 58CM ” med. fast post 1st class £10.95 |
|
|
MERCEDES R CLASS 251 VALVE BLOCK, A 251 320 01 58 £49.99 |
|
|
08 / 58 Mercedes-Benz C-class C220 Cdi Sport 2.1 5d Estate Auto Diesel BLACK £17,994.00 |
|
|
2008 58 MERCEDES-BENZ C CLASS £14,600.00 |
|
|
HERRINGBONE FLAT CAP WITH PREFORMED PEAK 58CM medium fast post 1st class £5.75 |
|
|
DAPOL – 103C CLASS 58 TRIPLE GREY SCETOR 58042 ‘N’ GAUGE. £68.00 |
|
|
Locomotives Illustrated Magazine Number 58 LMS Class 3P 2-6-2Ts £2.99 |
|
|
HORNBY OO BR CLASS 58 Co-Co DIESEL LOCO BOGIE SIDEFRAMES £1.75 |
|
|
Hornby R.250 Class 58 Diesel Co-Co – Running number 58001 £19.99 |
|
|
Hornby R.250 Class 58 Diesel Co-Co – Running number 58007 at one end of loco £24.99 |
|
|
Hornby R.250 Class 58 Diesel Co-Co – Running number 58007 at both ends of loco £29.99 |
|
|
Hornby R.283 Class 58 Diesel Co-Co Bassetlaw from 1989 R283 £37.99 |
|
|
QUALITY BLACK WOOL FELT FEDORA 58CM MEDIUM 7 1/8″ fast post 1st class £11.95 |
|
|
2008 58 MERCEDES-BENZ A CLASS 2.0 A180 CDI CLASSIC SE 5 £7,999.00 |
|
|
Railway Loco Photo BR Class 58 58045 BARROW HILL 22nd November 1986 RCTS Diesel £1.89 |
|
|
RAILFREIGHT DISTRIBUTION EMBROIDERED POLO SHIRT – CLASS 20 31 37 47 55 56 58 60 £11.00 |
|
|
RAILFREIGHT DISTRIBUTION EMBROIDERED POLO SHIRT – CLASS 20 31 37 47 55 56 58 60 £11.00 |
|
|
RAILFREIGHT DISTRIBUTION EMBROIDERED POLO SHIRT – CLASS 20 31 37 47 55 56 58 60 £11.00 |
|
|
RAILFREIGHT DISTRIBUTION EMBROIDERED POLO SHIRT – CLASS 20 31 37 47 55 56 58 60 £11.00 |
|
|
RAILFREIGHT DISTRIBUTION EMBROIDERED POLO SHIRT – CLASS 20 31 37 47 55 56 58 60 £11.00 |
|
|
RAILFREIGHT DISTRIBUTION EMBROIDERED POLO SHIRT – CLASS 20 31 37 47 55 56 58 60 £11.00 |
|
|
TOTON DEPOT BEANIE HAT – for CLASS 31 37 47 55 56 58 60 66 £6.00 |
|
|
64GB Class 10 High Speed SDXC Memory Card – Rollei Movieline SD-23 & more £44.99 |
|
|
WIDE BRIM BLACK STETSON COWBOY HAT 58cms medium 7 1/8″ fast post 1st class £6.95 |
|
|
MERCEDES C CLASS COUPE CL203 3.2 C 32 AMG KOMPRESSOR 05/02- EAF740 AIR FILTER 58 £20.11 |
|
|
MERCEDES E CLASS T MODEL S211 1.8 E 200 T KOMPRESSOR 03/03- EAF512 AIR FILTER 58 £20.33 |
|
|
Mercedes-Benz A Class A160 Cdi Classic SE 5d… 2008/58 £6,999.00 |
|
|
HORNBY GENERAL PURPOSE WIRING/SUPPRESSOR FOR CLASS 58 £1.99 |
|
|
LOCOS & COACHING STOCK 2003 – Class 20,25,31,33,37,40,45,47,50,56,58,60,66, DMU £0.99 |
|
|
LOCOS & COACHING STOCK 2005 – Class 20,25,31,33,37,40,45,47,50,56,58,60,66, DMU £0.99 |
|
|
Mercedes Benz S class Driver seat memory switch pack with mirror switch chas 220 £50.00 |
|
|
Hornby 00 Gauge R2345 Co-Co Diesel Electric Class 58 Locomotive BRAND NEW £49.99 |
|
|
Heljan Class 58 004 Railfreight Triple Grey excellent condition, fully boxed. £53.50 |
|
|
Pack of 10 AGE 10-12 Assorted Colour Childrens High Visibility Vest EN 471: Class 2 (MI58) £9.99 These brillaint vest are great for school activites, school trips and sports and games. They are 100% polyester. EN 471: CLASS 2 MAX: 25X Wash at 40 Degrees. YOU WILL RECIEVE 10 ASSORED COLOUR VEST. COLOURS ARE SUBJECT TO AVAILABILITY…. |
|
|
Pack of 10 AGE 7-9 Assorted Colour Childrens High Visibility Vest EN 471: Class 2 (MI58) £9.99 These brillaint vest are great for school activites, school trips and sports and games. They are 100% polyester. EN 471: CLASS 2 MAX: 25X Wash at 40 Degrees. YOU WILL RECIEVE 10 ASSORED COLOUR VEST. COLOURS ARE SUBJECT TO AVAILABILITY…. |
|
|
Pack of 10 AGE 4-6 Assorted Colour Childrens High Visibility Vest EN 471: Class 2 (MI58) £9.99 These brillaint vest are great for school activites, school trips and sports and games. They are 100% polyester. EN 471: CLASS 2 MAX: 25X Wash at 40 Degrees. YOU WILL RECIEVE 10 ASSORED COLOUR VEST. COLOURS ARE SUBJECT TO AVAILABILITY…. |
|
|
Karaoke: Reunion Series Class of 58 [CASSETTE] £6.99 … |
|
|
Fonzie Shuffle … |
|
|
FONZIE SHUFFLE 7 INCH (7 VINYL 45) UK BIRDSNEST … |
|
|
Loco Haulage Kensington Olympia 1997 (Video Tape/PAL) LOCO HAULAGE 1997: KENSINGTON OLYMPIA This video was filmed from the end of March to June 1997. It shows class 47s on container trains, passenger trains and hauling class 92 locos from Dollands Moor to Willesden and return. Class 37s are seen on engineering workings, class 58s on steel and 59s & 60s on stone trains. The following named locos are seen, as well as many more unnamed examples. 47764 R… |
|
|
Toton – The Works [Locomaster Profiles] (Video Tape/PAL) TOTON TRACTION MAINTENANCE DEPOT is the single largest locomotive workshop in the UK. With an allocation of more than 200 locomotives, the depot undertakes a variety of work ranging from A Exams and re-fuelling to engine rebuilds and general overhauls TOTON SPOT CHECK: stripping of 37401 prior to overhaul, engine repairs to a Virgin Class 47, cleansing the bodyside Class 58, overhaul Freightliner… |
|
|
Kanlux MB58 Steel B2 class induction ballast for stabilizing linear fluorescent lamp 18W IP Rating 20 Product information * core made of steel sheet Kanlux products offered by www.theinternetelectricalstore.com come with a full manufacturers warranty, and are available in many different types of fittings and styles. All products come with full EU … |
|
|
AC 30/5A Current Rectangle Panel Meter Analog Amperemeter Gauge £5.22 Color: Black, White; Net Weight: 78g; Package Content: 1 x Analog Ammeter, Several Installing Parts; Measures current range of AC 30/5A with accuracy of Class 2.5; |